We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christopher Wood

Christopher G. Wood MD, FACS

Professor of Urology; Vice Chairman, Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. Christopher G. Wood is Professor and Vice Chairman in the Department of Urology at The University of Texas MD Anderson Cancer Center. He is board certified through the American Board of Urology and is a Fellow of the American College of Surgeons. Dr. Christopher Wood is also a member of the Board of Directors, Medical Advisory Board, and Steering Committee of the Kidney Cancer Association. His major clinical focus is in the treatment of localized, locally advanced, and metastatic renal cell carcinoma. He has active clinical research protocols that focus on the development of minimally invasive techniques for patients with clinically localized disease, the development of effective adjuvant therapy for patients with locally advanced disease at high risk for relapse, and the integration of surgery with systemic therapy in the metastatic setting. Dr. Wood has an active, federally funded, basic science research program that is focused on the identification of aberrant molecular pathways that are critical to renal cell carcinogenesis and cancer progression. Using genomic and proteomic technologies, Dr. Wood’s laboratory has identified molecular markers of renal cell carcinoma that are altered and present in serum and tissue that are being developed as future clinical targets to aid in the diagnosis and treatment of renal cell carcinoma.

Disclosures

Pfizer:  Research support

Argos:  Research support

Glaxo Smith Kline:  Research support